Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012;17(10):1223-4.
doi: 10.1634/theoncologist.2012-0368. Epub 2012 Sep 21.

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

Vernon K Sondak  1 , Ragini Kudchadkar
Affiliations
Comment

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

Vernon K Sondak et al. Oncologist. 2012.

Abstract

The article by Herndon and colleagues on the approval of peginterferon-alfa-2b for the adjuvant treatment of patients with resected node-positive melanoma, published in this issue of The Oncologist, is examined, and the relevance of this therapy in clinical practice discussed.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Vernon K. Sondak: Merck (C/A, H, expert testimony). The other author indicated no financial relationships.

Comment on

References

    1. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet. 2005;366:1189–1196. - PubMed
    1. Herndon TM, Demko SG, Jiang X, et al. U.S. Food and Drug Administration approval: Peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. The Oncologist. 2012;17:1323–1328. - PMC - PubMed
    1. Daud AI, Xu C, Hwu WJ, et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011;67:657–666. - PMC - PubMed
    1. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117–126. - PubMed
    1. Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of ≥1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol. 2010;28:841–846. - PubMed

LinkOut - more resources